Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of MK-5172 with/without MK-8742 and/or ribavirin in treatment-naive chronic hepatitis C genotype 2, 4, 5 and 6
2013-002169-21Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of grazoprevir, verubecestat and ribavirin in chronic hepatitis C (CHC) and Chronic Hepatitis C Virus Infection (CHC), sponsored by Merck & Co. Primary endpoint: SVR12. Started Aug 2013; status: completed.
02
Drugs
grazoprevirverubecestatribavirin
03
Conditions
chronic hepatitis C (CHC)Chronic Hepatitis C Virus Infection (CHC)
Beyond the preview
Go deeper on 2013-002169-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002169-21.